STANDARD_NAME	HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_UP
SYSTEMATIC_NAME	M40920
COLLECTION	C7:VAX
MSIGDB_URL	https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_UP
NAMESPACE	HUMAN_GENE_SYMBOL
DESCRIPTION_BRIEF	Genes up-regulated in peripheral blood mononuclear cell vaccinated vs unvaccinated in adolescent/young adults (11-22) (low antibody responders to treatment) after exposure to M-M-R II , time point 7Y
DESCRIPTION_FULL	BACKGROUND: There are insufficient system-wide transcriptomic (or other) data that help explain the observed inter-individual variability in antibody titers after measles vaccination in otherwise healthy individuals. METHODS: We performed a transcriptome(mRNA-Seq)-profiling study after in vitro viral stimulation of PBMCs from 30 measles vaccine recipients, selected from a cohort of 764 schoolchildren, based on the highest and lowest antibody titers. We used regression and network biology modeling to define markers associated with neutralizing antibody response. RESULTS: We identified 39 differentially expressed genes that demonstrate significant differences between the high and low antibody responder groups (p-value <= 0.0002, q-value <= 0.092), including the top gene CD93 (p < 1.0E-13, q < 1.0E-09), encoding a receptor required for antigen-driven B-cell differentiation, maintenance of immunoglobulin production and preservation of plasma cells in the bone marrow. Network biology modeling highlighted plasma cell survival (CD93, IL6, CXCL12), chemokine/cytokine activity and cell-cell communication/adhesion/migration as biological processes associated with the observed differential response in the two responder groups. CONCLUSION: We identified genes and pathways that explain in part, and are associated with, neutralizing antibody titers after measles vaccination. This new knowledge could assist in the identification of biomarkers and predictive signatures of protective immunity that may be useful in the design of new vaccine candidates and in clinical studies.
PMID	27529750
GEOID	
AUTHORS	Haralambieva IH,Zimmermann MT,Ovsyannikova IG,Grill DE,Oberg AL,Kennedy RB,Poland GA
CONTRIBUTOR	HIPC SIGNATURES
CONTRIBUTOR_ORG	NIAID/HIPC SIGNATURES
EXACT_SOURCE	Table 1
FILTERED_BY_SIMILARITY	
EXTERNAL_NAMES_FOR_SIMILAR_TERMS	
EXTERNAL_DETAILS_URL	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987012/table/pone.0160970.t001/
SOURCE_MEMBERS	AK4,BCL2A1,CHST7,CYP1A1,IL36RN,IL6,ITGB8,LIF,MET,MSC,NAMPT,OR52N4,RFX8,TRPA1
GENE_SYMBOLS	AK4,BCL2A1,CHST7,CYP1A1,IL36RN,IL6,ITGB8,LIF,MET,MSC,NAMPT,OR52N4,RFX8,TRPA1
FOUNDER_NAMES